Navigation Links
Liquichek Autoimmune Controls - Anti-Mitochondrial

ProductsLiquichek Autoimmune Controls - Anti-Mitochondrial
Company Bio-Rad Laboratories
Item Liquichek Autoimmune Controls - Anti-Mitochondrial
Features 
  • Liquid, human serum based
  • 2 year shelf life at 28C
  • 60 day open-vial stability at 28C
Description Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays.
Info Bio-Rad Laboratories
Customer Service: 1-800-2-BIORAD
Web site: http://www.bio-rad.com

Related medicine products :

1. Liquichek Rheumatoid Factor Control
2. Liquichek Immunology Control
3. Liquichek Immunoassay Plus Control
4. Liquichek Spinal Fluid Control
5. Liquichek Urine Chemistry Control
6. Liquichek Whole Blood Volatiles Control
7. Liquichek Urinalysis Control
8. Liquichek Serum Volatiles Control
9. Liquichek Therapeutic Drug Monitoring Control (TDM)
10. Liquichek Autoimmune Controls - ANA
11. Liquichek Pediatric Control
The Contoured Wrist/Forearm Support provides comfort for post-surgical immobilization, post-fracture casting, and wrist sprains and strains.
ManuTrain is an active wrist support that has optional features for increased stabilization.
...he Hand and Wrist Cryo/Cuff combines the therapeut...hemarthrosis and swelling, and cold to minimize pa...be repositioned for desired hand coverage. ,For a... cuff and can be removed if a wider range of motio...
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
Medicine Products:
(Date:7/25/2008)...ter financial results -, LAVAL, QC, July 25 /PRNe...AQ: DDSS) today announced that it will host a conf...to discuss its second quarter 2008,financial resul...financial,results via news release at approximatel...ce call by telephone, dial 416-646-3095 or,1-800-8...
(Date:7/25/2008)...oviral therapy may be due to genetic factors , ... study challenges the long-held belief that the he...ability to restore itself after HIV patients are t...HAART). , From 50 percent to 90 percent of HIV-...travenous drug use is the main cause of both types...
(Date:7/25/2008)...American Society for Gastrointestinal Endoscopy (A...y in the bariatric surgery patient. The rising pre...ccess in surgical interventions led to a marked in...ormed in the U.S., from 13,365 in 1998 to 102,794 ...reoperative patient and the postoperative patient,...
(Date:7/25/2008)...mber of jobs created in the medical field slowed i...ent kind of slowdown: they laid off fewer people i... Seattle, WA (PRWEB) July 25, 2008 -- Thou... slowed in June overall, pharmaceutical companies ... music to the ears of sales representatives: fewer...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3
...ant constituents of foods in the cereal category a...s an integral part of health-conscious consumers. ...t more of the soluble oat fiber called beta-glucan...has been developed by Agricultural Research Servic...
...skin cancer is the most common tumor to be diagnos...researchers from University Hospital of Navarra. /...g steadily over the recent years. It is the number.... In the U.S., the number of new cases has risen f...
...linic scientists have unearthed a new virus in hum...und in mice, but not in humans. While it is too ea...virus and // prostate cancer is, the study aims to...entists say that this new discovery was made by us...
...loped a biosensor to detect the E. Coli bacteria, .... The biosensor is said to detect the bacteria rap...loped by the University of Rochester Medical Centr...ia as part of the sensing system that includes a s...
Other Medicine News:Health News:New Technique Could Revolutionize Melanoma Diagnosis and Treatment 2
(Date:7/22/2008)...-of-the-Art PET Study Confirms Tyrima Exhibits Exc...erties - - Results Support Initiation of Pha...N.C., July 22 /- CeNeRx BioPharma,In...cializing innovative,treatments for diseases of th... advance its lead candidate Tyrima(TM) into Phase ...
(Date:7/22/2008)...H SAN FRANCISCO, Calif., July 22 /- H... has completed patient enrollment,in its Phase 1/2...ty and,ammonia scavenging effects of HPN-100 (form...lbutyrate) in patients with urea cycle disorders,(...ts in the fourth quarter,of this year., (Logo: h...
(Date:7/22/2008)...y to Launch Innovative Laser Lipolysis Technology ...ion, WESTFORD, Mass., July 22 /PRNewswire-FirstCa...developer and manufacturer of a broad array of,lig... the European CE Mark,for Smartlipo MPX(TM), the c...orkstation to liquefy fat and tighten skin through...
(Date:7/22/2008)...t Study Suggests That Ekkyo,s New Approach of LASH... Improve Scar Healing Physiology, MARSEILLES, Fra... as,Heatwave Technology) a photomedicine company, ...for skin scar prevention and reduction, announced ...asers in Surgery and Medicine*,reporting the resul...
Breaking Medicine Technology:CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 2Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 3Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Also in the July 8 JNCI 23519 1Also in the July 8 JNCI 23519 2Also in the July 8 JNCI 23519 3Also in the July 8 JNCI 23519 4Iowa State researchers study ground cover to reduce impact of biomass harvest 3949 1Iowa State researchers study ground cover to reduce impact of biomass harvest 3949 2Iowa State researchers study ground cover to reduce impact of biomass harvest 3949 3Iowa State researchers study ground cover to reduce impact of biomass harvest 3949 4Cancer Care Unaffected by Doctor Reimbursement Changes 23514 1Cancer Care Unaffected by Doctor Reimbursement Changes 23514 2College Educated Fare Better When Cancer Strikes 23510 1College Educated Fare Better When Cancer Strikes 23510 2College Educated Fare Better When Cancer Strikes 23510 3
... -- ImClone,Systems Incorporated and Bristol-Myers...tudy of ERBITUX(R) (Cetuximab) plus,gemcitabine (a...nresectable or metastatic pancreatic cancer did no...urvival. , Conducted by the Southwest Oncology Gro...e National Cancer Institute, the,open-label, rando...
...on management,programs, ST. PAUL, Minn., April 10,...me Therapeutics (Prime) today announced the result...tomoxetine) for treating,attention deficit hyperac...d that children who start on Strattera were 4.2 ti...ren who started on,stimulants. Due to these result...
Other Medicine Technology:Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 2Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 3Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 4Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 5Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 6Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 7Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 8Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer 9Study Shows Children With ADHD Who Start on Strattera are More,Likely to Change Therapies 2Study Shows Children With ADHD Who Start on Strattera are More,Likely to Change Therapies 3